SEC Filings

Form 8-K Kala Pharmaceuticals, For: May 16 May 16, 2022 07:07AM

Exhibit 99.1

​

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

- Expanded Coverage for EYSUVIS® to 92% of Total Commercial Lives and 30% of All Medicare Lives -

- Achieved 18% EYSUVIS Prescription Growth in 1Q 2022 -

- Presented KPI-012 Phase 1b Clinical Data at ARVO; Initiation of Phase 2/3 Clinical Trial in PCED Expected 4Q 2022 -

- Conference Call and Webcast at 8:00 a.m. ET -

​

ARLINGTON, Mass., May 16, 2022 – Kala Pharmaceuticals, Inc.... (continue reading...)

Form 13F-HR Abingworth LLP For: Mar 31 May 16, 2022 07:07AM .FormData { color: blue; background-color: white; font-size: small; font-family: Times, serif; } .FormDataC { color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center; } .FormDataR { color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align:... (continue reading...)

Form 15-12B DraftKings Holdings Inc. May 16, 2022 07:07AM

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number: 001-38908

 

DraftKings Holdings Inc.*

 

(Exact name of Issuer as specified in its charter)

 

222 Berkeley Street,... (continue reading...)

Form 8-K Protalix BioTherapeutics For: May 16 May 16, 2022 07:07AM

Exhibit 99.1

​

Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results

Company to host conference call and webcast today at 8:30 a.m. EDT

CARMIEL, Israel, May 16, 2022 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today... (continue reading...)

Form 8-K Timberline Resources For: May 11 May 16, 2022 07:07AM tlrs_8k.htm0001288750false00012887502022-05-112022-05-11iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report:May 11, 2022

(Date of earliest event reported)

 

Timberline Resources Corporation

(Exact name of registrant as specified in its charter)

 

Commission File Number: 001-34055

... (continue reading...)